# Use of 3 HIV testing methods in French primary care setting: ELISA laboratory screening versus two rapid finger-stick HIV tests,

under five minute (INSTI) and under 30 minute (VIKIA) tests

Daiana Papadima <sup>1,2</sup>, Raphaël Gauthier <sup>2,3,4</sup>, François Prévoteau du Clary <sup>2,5</sup>, Jean-Pierre Aubert <sup>2,3,4</sup>, Stéphane Bouée <sup>2,6</sup>, Guillaume Conort <sup>2,7</sup>, Jean-Michel Livrozet <sup>2,8</sup>, Jean-Michel Peter <sup>2,12</sup>, Olivier Taulera <sup>2,9</sup>, Alain Wajsbrot <sup>2,10</sup>, Catherine Majerholc <sup>2,3,4,11</sup>

- <sup>1</sup> Département de Médecine Générale, Université Louis Pasteur Strasbourg, France
- <sup>2</sup> Groupe d'études et recherche ville-hôpital : 75 rue du Ruisseau, Paris, France <sup>3</sup> Univ Paris Diderot, Sorbonne Paris Cité, Dept Med Gen, F-75018 Paris, France
- <sup>4</sup> EA Recherche Clinique Coordonnée Ville-Hôpital, Méthodologies et Société (REMES), F-75018 Paris, France
- <sup>5</sup> Hôpital La Grave, Hôpitaux de Toulouse, France <sup>6</sup> Cemka Eval, 43 Boulevard du Maréchal Joffre, 92340 Bourg-la-Reine, France
- <sup>7</sup> Département de Médecine Générale, Université de Bordeaux, France

8 Service des maladies infectieuses et tropicales, Hôpital Edouard Herriot, Lyon, France

- <sup>9</sup> Hôpital Saint Louis, Paris, France <sup>10</sup> Médecine Générale, Hôpital d'Avignon, France
- 11 Service de médecine interne, Hôpital Foch, Suresnes, France <sup>12</sup> Groupe Hospitalier Mulhouse Sud-Alsace, France



# **Background**

- In 2009, French national guidelines recommended widespread routine HIV screening, reinforcement of regular targeted screening of at-risk groups and/or depending on circumstances. Promotion of rapid point of care HIV tests (RHT) to expand HIV screening began.
- Five years later, unpromising results: low increase in HIV testing, persistance of hidden HIV epidemics (around 29 000 people unaware being HIV+)
  - ✓ Studies led in the emergency room setting¹ showed a low feasability of the mass screening strategy;  $\checkmark$  The missed opportunities study<sup>2</sup> showed that MDs could employ targeted screening based on risk groups and/or clinical signs.
  - ✓ The Morlat experts' group report<sup>3</sup> and the GPs National Council<sup>4</sup> insist on risk factor based screening
- RHT feasability and interest in French general practice, little amount of data:
  - ✓ DEPIVIH: Good acceptability but limited feasibility of rapid HIV testing (VIKIA) in GPs office due to time restriction, technical difficulties and staff training<sup>5</sup>,
  - ✓ Efficient strategy in Guyane (highest HIV prevalence in France) with financial support from social security<sup>6</sup>,
  - ✓ The joint screening of HIV, HBV and HCV after appropriate training of motivated GPs improved testing rates, even after a short period, particularly within at-risk groups7.
- Hypothesis: simultaniously offering GPs 3 screening tools from which to choose could help establish the most suitable HIV screening strategy for general practice and hence diminish hidden HIV epidemics.
- We designed a new study titled DEPIVIH 2. In addition to VIKIA RHT, we introduced the immediate answer RHT INSTI test and left the possibility of using Elisa blood tests.

#### Methods

- National prospective interventional study led in French GPs offices between December 2013 and December 2014.
- > Primary outcome: to assess the use of 3 screening methods in French GPs current HIV screening practice:
  - ✓ ELISA test prescription,
  - ✓ immediate answer RHT INSTI (Nephrotek),
  - ✓ or 30 min delayed answer RHT VIKIA (BioMérieux).



**Medical activity of the GPs** 

Urban area

Rural area

Part time clinic hours

Yes

No

UNK

UNK – unknown

Suburban area

Practice area



INSTI

Investigators

43 GPs, mean age 46 years old,

48.8% women,

One-third in practice since 2009

- > Adult patients over 18 YOA of unknown HIV status that visited their physician were eligible for study.
- > HIV testing was performed following spontaneous patient request, routine physician recommendation, or on a targeted basis.
- > Secondary endpoints:

N= 43

38 (88.4%)

4 (9.3%)

1 (2.3%)

17 (43.6%)

22 (56.4%)

36 (83.7%)

318.5 (125.7)

37 (86%)


18.0 (38.2)

36 (83.7%)

55.3 (119.1)

- ✓ Screening rate of population with unknown HIV status consulted during the study period,
- ✓ Screening circumstances and reasons for the choice of the screening method,
- ✓ Investigators satisfaction regarding RHT and problems encountered


**Population: screened** 



23 tests/GP = 18 Elisa tests and 5 RHT Mean use profile

Total

# Use of each screening method



■INSTI ■VIKIA Elisa blood test

HIV test results			
Test results	Elisa Blood Test	RHT	TOTAL
	n=767 (78.2%)	n=214 (21.8%)	n=981 (100%)
Positive Negative Invalid Unrecovered UNK	5 (0.7%)	4 (1.9%)	9 (0.9%)
	641 (83.6%)	203 (95.3%)	844 (86.0%)
		6 (2.8%)	6 (0.6%)
	120 (15.7%)	0	120 (12.5%)
	1	1	2

# UNK – unknown

>	9 new	ly diagnosed HIV infection (NDHI):
	$\checkmark$	7 men and 2 women

- Mean age: 37 years old,
- Tested after GPs' offer or in mutual agreement with patient,
- Mainly after targeted screening: 4 MSM and 5 migrants, 2/3 had previous screening history,
- With potentially HIV clinical signs (4/9) and comorbidities (2 with chronic HBV and one with chronic HCV).
- The 3 patients with medical history and regular follow-up for chronic hepatitis were diagnosed by RHT point of care.
- All NDHI were confirmed and all patients were linked to care.
- > NDHI were done by 5 GPs, in cities of Paris, Toulouse, Lyon and Marseille: 4 GPs have part time clinic duty in the follow-up of patients
  - suffering from chronic viral infections, Mean number of patients HIV+/month during the study ~ 78,
  - Screening rate 3% (3 times higher than the global study screening rate).

### **GPs satisfaction regarding RHT** 90.9% of GPs were globally satisfied with the RHT (97% by the

No of patients attending their practice last month

No of HIV+ adult patients attending their practice last month

Total no of HIV+ adult patients being followed by the GP

Total no of respondants

Total no of respondants

Mean (standard deviation)

Total number of repondants

Mean (standard deviation)

Mean (standard deviation)

- amount of time used for INSTI and 38.5% for VIKIA).
- 8 GPs/10 would continue using INSTI test in their current practice.

# **Principal problems:**

- Technical difficulties for 13.9% of RHT, mainly related to blood sampling.
- Positive test announcement:
  - same perceived difficulty with Elisa or RHT for 61.3%, 19.4% would find it more difficulty with RHT.
- 15.7% of the prescribed Elisa blood tests were not done by the patient.
- UNK unknown; (b) Student Test, (e) CHI2 Test

#### attending patients with p-value n=981(100%) n= 767 (78.2%) Vikia INSTI unknown HIV status. n=33 n=181 Gender 433 (56.5%) 535 (54.5%) 102 (47.7%) Female 0.0224 (e) 112 (52.3%) 446 (45.5%) Male 334 (43.5%) Age (years) 34.8 (12.0) 33.7 (11.9) 34.5 (12.0) 0.2431 (b) Mean (SD) **Previous HIV screening** history? 499 (67.3%) 653 (68.4%) 154 (72.0%) Yes 0.2003 (e) 242 (32.7%) 60 (28.0%) 302 (31.6%) No 26 26 UNK **Date of previous HIV test** 4 (2.7%) 7 (1.1%) 3 (0.6%) 1983-1993 38 (6.2%) 1994-2004 28 (7.0%) 10 (6.9%) 82 (13.3%) 70 (15.0%) 12 (8.1%) 2005-2009 121 (82.3%) 489 (79.4%) 368 (78.4%) 2010-2014 Who initiated the screening procedure? GP 469 (62.0%) 51 (23.9%) 522 (53.7%) Patient 71 (9.4%) 61 (28.6%) 132 (13.6%) <0.0001 (e) Both 216 (28.6%) 101 (47.5%) 317 (32.7%) 12 11 UNK **Reason for HIV** screening. Routine test 557 (75.0%) 123 (60.3%) 680 (71.8%) <0.0001 (e) Risk factor 77 (37.7%) 159 (21.4%) 236 (24.9%) 27 (3.6%) 31 (3.3%) Clinical signs 4 (2.0%) 24 10 34 UNK

Patients demographic characteristics and screening data

**Elisa Blood Test** 

RHT

n=214 (21.8%)

# Reasons for choosing Elisa blood test or RHT:

- < 3 months HIV exposure: 19% of Elisa blood tests vs 25% of RHT.
- Possible HIV primary infection or HIV clinical signs: 2.9% of Elisa blood tests and RHT.
- Opportunity to combine blood tests: 85.8% of
- Elisa tests. Opportunity of performing an RHT: 68.4% of
  - RHT. Rapidity of test result: 43.4% of RHT.
  - Certainty of having the test done and the result delivered: 15.1% of RHT. Fear of venous blood sampling: 11.8% of RHT.

# Conclusions

- Giving GPs several HIV testing methods led to significant screening activity.
- Elisa blood test was the most frequently chosen screening method, mainly by physicians, in order to combine with other blood analysis.
- RHT were done primarily on patient demand or after collective agreement.
- RHT INSTI was preferred due to its rapid result delivery.
- Most of the tests were routine screening procedures.
- 28.2% were targeted
  - ✓ mainly based on HIV risk factors, ✓ in lesser degree on HIV clinical signs.
- A significant part of RHT (~40%) was performed in targeted screening.
- screening tool.
- The significant part of the unfulfilled Elisa blood tests emphasizes RHT point of care as an alternative

- 9 new diagnoses of HIV infection were made (0.9% of 981 tests):
  - ✓ By RHT as well as Elisa blood test;,
  - ✓ After targeted screening: MSM and migrants; ✓ 5 diagnosed in Toulouse in «an acces to care» GPs practice;
  - ✓ By 5 GPs, among whom, 4 are frequently confronted with HIV epidemics.

✓ Recent office practice after 2009 (year of the release of the current guidelines by National)

- One third of GPs are aware of the importace of HIV screening:
- ✓ The role of additional medical intervention in follow-up of HIV positive patients;
- Rapid HIV tests used by GPs working in high HIV prevalence areas in France: ✓ Are a useful screening tool that expand on the reperetoire of HIV tests,
  - ✓ Are well-accepted by MDs, ✓ Allow the diagnosis of new HIV infections.

Health Authority) ~ more up to date.

They should be considered and promoted by healthcare authorities.

Dr. Kokougan C Dr. Di Pumpo A Dr. Provost AG Dr. Salaun A Dr. Lhuillier L Dr. Seif A Dr Bacle F Dr. Nougairede M Dr. Cordonnier Dr. Mourier Dr. Pillon N

Dr Catrice M

Dr Taulera O

Dr Golfier JB

Dr. Gauffier N

Dr. Catusse Dr Philibert Dr. Simon Cohen A Dr. Cadart Dr Wajbrot A Dr Regard P Dr Zanutini C Dr Goudilliere B Dr. Haag H Dr. Pinar M

Dr. Chauveau M

Dr. Lalande M

Dr. Leymarie

Dr. Melchior Y

Dr. Majerholc C

Acknowledgements to all the investigators:

Dr. Pariente K Dr. Prevoteau F Dr Wieser Dr Pellissier Dr. Willemain I Dr Leveque Dr Plaum Dr. Naessens M Dr Gueripel V Dr Godinot Dr Chiarello

Dr. Palaz Nafnef M

Dr. Adam M

<sup>1</sup> CASALINO E, BERNOT B, BOUCHAUD O, et al. Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study. PLoS One, 2012, vol.7, n°10, 8 p. <sup>2</sup> Karen Champenois Opportunités manquées de dépistage du VIH chez des patients nouvellement diagnostiqués en France EtudeANRS. Opportunités Online:www.anrs.fr/.../14%20%20%20Karine%20Champenois\_20120504.pdf <sup>3</sup> Professeur Philippe Morlat, CNS et ANRS. Prise en charge médicale des personnes vivant avec le VIH. Actualisation 2014 du rapport 2013 112 p. Online: <a href="http://www.sante.gouv.fr/IMG/pdf/experts-vih-actualisations2014.pdf">http://www.sante.gouv.fr/IMG/pdf/experts-vih-actualisations2014.pdf</a>. <sup>4</sup> Dépistage de l'infection par le VIH en médecine générale. Multiplier les propositions de test et privilégier l'entretien orienté. Henri Partouche et Vincent Renard. CNGE. Présentation orale 17 diapositives; Online: www.anrs.fr <sup>5</sup> GAUTHIER R, LIVROZET JM, PREVOTEAU DU CLARY F, et al. Feasibility and acceptability of rapid HIV test screening (DEPIVIH) by French family physicians. Médecine et maladies infectieuses, 2012, vol.42, n°11, pp. 553-560 <sup>6</sup>JOLIVET A, SANGARE I, DIMANCHE S, et al. Les tests rapides d'orientation diagnostiques (TROD) du VIH par les médecins libéraux : bilan d'un an d'expérimentation en Guyane. Bulletin de veille sanitaire Antibes-Guyane, 2012, n°10, pp. 18-20 <sup>7</sup> Catherine Fagard et al. Feasibility of joint screening for HIV, HBV and HCV by general practitioners in two French counties, 2012. Bulletin épidémiologique hebdomadaire N° 21-22 - 8 juillet 2014. pp 395-400